Prostate Cancer - Results from #80

Detection of MRI-Invisible Disease Using PSMA PET/CT in a Patient Considering Focal Therapy. April 4, 2025

LHRH Antagonists Restore Serum Testosterone Faster Than LHRH Agonists in Prostate Cancer Patients After Radiotherapy. April 4, 2025

Stereotactic body radiotherapy for lung oligometastatic prostate cancer: An international retrospective multicenter study. April 4, 2025

Analytical and Real-World Clinical Characterization of S2,3PSA% Test in MRI Fusion Targeted Prostate Biopsy Population. April 4, 2025

Geographic, socioeconomic and demographic inequalities in the incidence of metastatic prostate cancer at time of diagnosis in England: a population-based evaluation. April 4, 2025

High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes. April 3, 2025

Toward a Refined PI-RADS: The Feasibility and Limitations of More Informative Metrics in Reviewing MRI Scans. April 3, 2025

Early changes of PSMA PET expression after initiation of androgen receptor signaling inhibitors in CRPC: an international multicenter retrospective study. April 3, 2025

Targeting the tumour cell surface in advanced prostate cancer. April 3, 2025

Enzalutamide in biochemically recurrent prostate cancer: key findings from the EMBARK study. April 3, 2025

Advances in PSMA-Targeted Radionuclide Therapeutics. April 3, 2025

Lower Testosterone level and metastases-free survival in nmCRPC patients treated with novel antiandrogens: A post-hoc analysis of SPARTAN and ARAMIS. April 3, 2025

PSMA-PET guided Intra-prostatic Boost in Prostate SBRT (PROBE): A phase II trial. April 3, 2025

Darolutamide plus androgen-deprivation therapy: propensity score matching of ARASEC and historic clinical trial patients. April 2, 2025

Treatment Noncompletion and Shorter Radiation Regimens Among US Patients With Prostate Cancer: A Focus on Asian American and Pacific Islander Patients. April 2, 2025

Racial variation in the advanced prostate cancer genome. April 2, 2025

Prospective comparison of 18F-PSMA-1007 PET/CT and MRI with histopathology as the reference standard for intraprostatic tumour detection and T-staging of high-risk prostate cancer. April 2, 2025

Causes of evolutionary divergence in prostate cancer. April 2, 2025

Local anaesthetic transperineal biopsy versus transrectal prostate biopsy in prostate cancer detection (TRANSLATE): a multicentre, randomised, controlled trial. April 1, 2025

Prevalence and Medium-Term Outcomes of Patients with Biopsy-Proven Intermediate- to High-Risk Prostate Adenocarcinoma with Low Intraprostatic Uptake on [68Ga]Ga-PSMA-11 PET/CT in the proPSMA Study. April 1, 2025

Page 5 of 1473